Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: Evidence for an endothelin-mediated mechanism

Circulation

Volumn 100, Issue 18, 1999, Pages 1901-1908

  Boffa, Jean Jacques ^b   Tharaux, Pierre Louis ^b   Placier, Sandrine ^b   Ardaillou, Raymond ^b   Dussaule, Jean Claude ^a   Chatziantoniou, Christos ^a  

^a INSERM   (France)

^b Hôpital Tenon ^*

Author keywords

Angiotensin; Collagen; Endothelin; Hypertension; Kidney

Indexed keywords

ANGIOTENSIN; BOSENTAN; COLLAGEN TYPE 1; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; LOSARTAN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PROCOLLAGEN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FIBROSIS; GENE; GENE ACTIVATION; HYPERTENSION; KIDNEY BLOOD VESSEL; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SYNTHESIS; TRANSGENIC MOUSE;

EID: 0033517863     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.18.1901     Document Type: Article

References (32)

1. Weistuch JM, Dworkin LD. Does essential hypertension cause end-stage renal disease? Kidney Int. 1992;41:S33-S37.
2. Yoshioka K, Tohda M, Takemura T, Akano N, Matsubara K, Ooshima A, Maki S. Distribution of the type I collagen in human kidney diseases in comparison with type III collagen. J Pathol. 1990;162: 141-148.
3. Anderson S, Meyer TW, Renke HG. Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1985;76:612-619.
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
5. Border WA, Noble NA. Interactions of transforming growth factor-β and angiotensin II in renal fibrosis. Hypertension. 1998;31(pt 2):181-188.
6. Xu Y, Arnal JF, Hinglais N, Appay MD, Laboulandine I, Bariety J, Michel JB. Renal hypertensive angiopathy: comparison between chronic NO suppression and DOCA-salt intoxication. Am J Hypertens. 1995;8:167-176.
7. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest. 1992;90:278-281.
8. Li JS, Larivière R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats: evidence for a role of endothelin in vascular hypertrophy? Hypertension. 1994;24:183-188.
9. A-receptor antagonist. Circulation. 1997;96: 1593-1597.
10. Bouriquet N, Dupont M, Herizi A, Mimran A, Casellas D. Preglomerular sudanophilia in L-NAME hypertensive rats: involvement of endothelin. Hypertension. 1996;27:382-391.
11. Chatziantoniou C, Boffa JJ, Ardaillou R, Dussaule JC. Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice: role of endothelin. J Clin Invest. 1998;101:2780-2789.
12. 2(I) collagen gene regulates expression of reporter genes in transgenic mice. J Cell Biol. 1996;134:1333-1344.
13. Tharaux PL, Chatziantoniou C, Casellas D, Fouassier L, Ardaillou R, Dussaule JC. Vascular endothelin-1 gene expression, synthesis, and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats. Circulation. 1999;99: 2185-2191.
14. Namaguchi K, Egashira K, Takemoto M, Kadokami T, Shimokawa H, Sueishi K, Takeshita A. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension. 1995;26:957-962.
15. Katoh M, Egashira K, Usui M, Ichiki T, Tomita H, Shimokawa H, Rakugi H, Takeshita A. Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ Res. 1998;83:743-751.
16. Weber K. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation. 1997;96:4065-4082.
17. Crawford DC, Chobanian AV, Brecher P. Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. Circ Res. 1994;74:727-739.
18. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol. 1994;26:809-820.
19. Ju H, Dixon IMC. Effect of angiotensin II on myocardial collagen gene expression. Mol Cell Biochem. 1996;163/164:231-237.
20. Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, Shimokawa H, Sueishi K, Takeshita A. Important role of tissue angiotensin converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest. 1997;99: 278-287.
21. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, Drexler H. Comparative effects of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation. 1994; 89:2273-2282.
22. Michel JB, Xu Y, Blot S, Philippe M, Chatellier G. Improved survival in rats administered L-NAME due to converting enzyme inhibition. J Cardiovasc Pharmacol. 1996;28:142-148.
23. Rajagopalan S, Laursen JB, Borthayre A, Kurtz S, Keiser J, Haleen S, Giaid A, Harrison DG. Role for endothelin-1 in angiotensin II-mediated hypertension. Hypertension. 1997;30:29-34.
24. d'Uscio LV, Shaw S, Barton M, Luscher TF. Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: role of blood pressure and endothelial function. Hypertension. 1998;31: 1305-1310.
25. Casellas D, Bouriquet N, Herizi A. Bosentan prevents preglomerular alterations during angiotensin II hypertension. Hypertension. 1997; 30:1613-1620.
26. Clavel AL, Mattingly MT, Stevens TL, Nir A, Wright S, Aarhus LL, Heublein DM, Burnett JC. Angiotensin-converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. J Clin Invest. 1996;97:1286-1292.
27. Largo R, Gomez-Garre D, Liu XH, Alonso J, Blanco J, Plaza JJ, Egido J. Endothelin-1 upregulation in the kidney of uninephrectomized spontaneously hypertensive rats and its modification by the angiotensin-converting enzyme inhibitor quinapril. Hypertension. 1997;29: 1178-1185.
28. Lariviere R, Lebel M, Kingma I, Grose JH, Boucher D. Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli in rats with reduced renal mass. Am J Hypertens. 1998;11: 989-997.
29. Cottone S, Vadala A, Vella MC, Nardi E, Mule G, Contorno A, Riccobene R, Cerasola G. Changes of plasma endothelin and growth factor levels, and of left ventricular mass, after chronic AT1-receptor blockade in human hypertension. Am J Hypertens. 1998;11:548-553.
30. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature. 1992;360:361-364.
31. Tomita H, Egashira K, Ohara Y, Takemoto M, Koyanagi M, Katoh M, Yamamoto H, Tamaki K, Shimokawa H, Takeshita A. Early induction of TGF-β via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension. 1998;32:273-279.
32. Sütsch G, Kiowski W, Yan X, Hunziker P, Christen S, Strobel W, Kim J, Rickenbacher P, Bertel O. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 1998;98:2262-2268.